Literature DB >> 22416599

Extracorporeal bioartificial liver for treating acute liver diseases.

Ashok Kumar1, Anuj Tripathi, Shivali Jain.   

Abstract

UNLABELLED: Liver is a vital organ of the human body performing myriad of essential functions. Liver-related ailments are often life-threatening and dramatically deteriorate the quality of life of patients. Management of acute liver diseases requires adequate support of various hepatic functions. Thus far, liver transplantation has been proven as the only effective solution for acute liver diseases. However, broader application of liver transplantation is limited by demand for lifelong immunosuppression, shortage of organ donors, relative high morbidity, and high cost. Therefore, research has been focused on attempting to develop alternative support systems to treat liver diseases. Earlier attempts have been made to use nonbiological therapies based on the use of conventional detoxification procedures such as filtration and dialysis. However, the absence of liver cells in such techniques reduced the overall survival rate of the patients and led to inadequate essential liver-specific functions. As a result, there has been growing interest in the development of biological therapy-based extracorporeal liver support systems as a bridge to liver transplantation or to support the ailing liver. A bioartificial liver support is an extracorporeal device through which plasma is circulated over living and functionally active hepatocytes packed in a bioreactor with the aim to aid the diseased liver until it regenerates or until a suitable graft for transplantation is available. This review article gives a brief overview of efficacy of various liver support systems that are currently available. Also, the development of advanced liver support systems, which has been analyzed for improving the important system component such as cell source and other culture and circulation conditions for the maintenance of the liver-specific functions, have been described. KEYWORDS: liver failure, hepatocytes, liver support devices, bioartificial liver, bioreactor.

Entities:  

Mesh:

Year:  2011        PMID: 22416599      PMCID: PMC4557422     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  69 in total

1.  Subdivision of hexagonal liver lobules into a structural and functional unit; role in hepatic physiology and pathology.

Authors:  A M RAPPAPORT; Z J BOROWY; W M LOUGHEED; W N LOTTO
Journal:  Anat Rec       Date:  1954-05

2.  Hollow fiber bioartificial liver utilizing collagen-entrapped porcine hepatocyte spheroids.

Authors:  F J Wu; J R Friend; A Lazar; H J Mann; R P Remmel; F B Cerra; W S Hu
Journal:  Biotechnol Bioeng       Date:  1996-10-05       Impact factor: 4.530

3.  Comparative evaluation of different membranes for the construction of an artificial liver support system.

Authors:  S Qiang; Y Yaoting; L Hongyin; H Klinkmann
Journal:  Int J Artif Organs       Date:  1997-02       Impact factor: 1.595

4.  Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure.

Authors:  A J Ellis; R D Hughes; J A Wendon; J Dunne; P G Langley; J H Kelly; G T Gislason; N L Sussman; R Williams
Journal:  Hepatology       Date:  1996-12       Impact factor: 17.425

5.  Delayed encephalopathy in fulminant hepatic failure in the pediatric population and the role of liver transplantation.

Authors:  T Rivera-Penera; J Moreno; C Skaff; S McDiarmid; J Vargas; M E Ament
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-02       Impact factor: 2.839

Review 6.  Fulminant and subfulminant liver failure: definitions and causes.

Authors:  J Bernuau; B Rueff; J P Benhamou
Journal:  Semin Liver Dis       Date:  1986-05       Impact factor: 6.115

Review 7.  A bioartificial liver--state of the art.

Authors:  Alastair J Strain; James M Neuberger
Journal:  Science       Date:  2002-02-08       Impact factor: 47.728

8.  Development of a bioartificial liver employing xenogeneic hepatocytes.

Authors:  W S Hu; J R Friend; F J Wu; T Sielaff; M V Peshwa; A Lazar; S L Nyberg; R P Remmel; F B Cerra
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

9.  Clinical use of a bioartificial liver in the treatment of acetaminophen-induced fulminant hepatic failure.

Authors:  O Detry; N Arkadopoulos; P Ting; E Kahaku; F D Watanabe; J Rozga; A A Demetriou
Journal:  Am Surg       Date:  1999-10       Impact factor: 0.688

10.  A technique for porcine hepatocyte harvest and description of differentiated metabolic functions in static culture.

Authors:  T D Sielaff; M Y Hu; S Rao; K Groehler; D Olson; H J Mann; R P Remmel; R A Shatford; B Amiot; W S Hu
Journal:  Transplantation       Date:  1995-05-27       Impact factor: 4.939

View more
  4 in total

1.  Implications of differential stress response activation following non-frozen hepatocellular storage.

Authors:  William L Corwin; John M Baust; John G Baust; Robert G Van Buskirk
Journal:  Biopreserv Biobank       Date:  2013-02       Impact factor: 2.300

Review 2.  The Potential Clinical Use of Stem/Progenitor Cells and Organoids in Liver Diseases.

Authors:  Christina Nikokiraki; Adriana Psaraki; Maria G Roubelakis
Journal:  Cells       Date:  2022-04-21       Impact factor: 7.666

3.  Development of liver microtissues with functional biliary ductular network.

Authors:  Ehab O A Hafiz; Beyza Bulutoglu; Soheir S Mansy; Yibin Chen; Hoda Abu-Taleb; Somia A M Soliman; Ali A F El-Hindawi; Martin L Yarmush; Basak E Uygun
Journal:  Biotechnol Bioeng       Date:  2020-09-14       Impact factor: 4.530

4.  A novel, simplified, and reproducible porcine model of acute ischemic liver failure with portal vein preservation.

Authors:  Weisong Xue; Yu Fu; Haojie Zhang; Guoping Li; Peihua Cao; Yang Li; Qing Peng; Kebo Zhong; Shuangtang Feng; Yi Gao
Journal:  Exp Anim       Date:  2021-09-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.